Varian Medical Systems — Q1 2018 Earnings Presentation
36 slides from Varian Medical Systems's earnings presentation, Jan 24, 2018
Slide 1: First Quarter Fiscal Year 2018
J. Michael Bruff Vice President, Investor Relations [email protected] January 24, 2018 First Quarter Fiscal Year 2018
Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1
Slide 3: Long-Term Strategy
Long - Term Strategy
Slide 4: Global leader in radiation therapy
Eclipse ™ Treatment planning system RapidPlan ™ Knowledge - based planning software Calypso ® Real - time tracking technology Edge ™ System Full - body radiosurgery platform Halycon ™ Image - guided IMRT treatment platform TrueBeam ® /VitalBeam ™ Trilogy ® /Clinac ® /UNIQUE ™ Treatment procedures wi
Slide 5: Long-term growth and value creation strategy
Long - term growth and value creation strategy 5 Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology
Slide 6: Expand addressable market to patient-centered care coordination
Long - term growth and value creation strategy Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions 6 Interventional oncology Surgical oncology Diagnostic imaging Radiation oncology Precision medicine Medical oncology Generate insights Call on all oncologists Aggregate data Dissem
Slide 7: Growth priorities and strategic enablers
Growth priorities and strategic enablers 7 We are here Global Leader in Radiation Therapy Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions Long - Term Growth and Value Creation Strategy Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Marke
Slide 8: Growth priority: Strengthen our leadership in radiation therapy
Growth priority: Strengthen our leadership in radiation therapy (1) Based on company estimates and industry reports and data Executing on HyperArc launch our high - definition radiotherapy technology ⁃ 19 orders in the first quarter ⁃ 60% are upgrades Global market leader in radiation therapy, incre
Slide 9: Growth priority: Extend global footprint
Growth priority: Extend global footprint 55% international orders mix in Oncology; 12% international orders growth ⁃ EMEA orders growth of 19% ⁃ APAC orders growth of 6% ⁃ Latin American orders growth of - 3% 40% of Halcyon orders in emerging markets, since May launch ⁃ ~90% of emerging market order
Slide 10: Growth priority: Expand addressable market
Growth priority: Expand addressable market Financial flexibility to evaluate investment opportunities including both organic and inorganic options ⁃ Cash flow from operations grew 118% ⁃ Decreased debt across the year Unique software customers grew 4% during the first quarter; newer applications fue
Slide 11: 1Q FY 2018 Business Highlights
1Q FY 2018 Business Highlights
Slide 12: Year in review
First patient treated with Varian HyperArc high - definition radiotherapy Varian publishes 2017 Sustainability Report Year in review 12 JANUARY 2017 FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DECEMBER 2017 Varian honored as one of the top 100 most sustainable companies Spin - off of Varex Varian names
Slide 13: Financial highlights
Cash Flow from Operations 1 ($M) $0 $50 $100 $150 $200 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Non - GAAP EPS ($) $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Financial highlights Operating Trends* Strong performance in key financial measures • Revenues up 13% due to h
Slide 14: Varian linac install base
Varian linac install base Install Base Trends Varian strengthened its global leadership in radiation therapy • Each geography grew respective install base in the first quarter 14 Q1FY17 Q3FY17 Q2FY17 Q4FY17 Q1FY18 7,630 Total 7,876 +3%
Slide 15: Key wins
Key wins Americas EMEIA APAC Spain – Osakidetza 2 TrueBeams Denmark tender 15 linacs – Mix of TrueBeams and Halcyon over 4 years Poland Ministry of Health national tender 5 linac s – 1 Halcyon, 1 TrueBeam , 3 VitalBeams India Agartala and Jaipur cancer centers 5 linacs – 2 TrueBeams , 3 Unique Alaba
Slide 16: 1Q FY 2018 Financial Overview
1Q FY 2018 Financial Overview
Slide 17: Varian consolidated (GAAP) Key P&L Financial Metrics
Varian consolidated (GAAP) Key P&L Financial Metrics 17 VARIAN FISCAL 2018 $M 1Q Y/Y Gross Orders $666 15% Revenues $679 13% Product $366 18% Services $313 7% Gross Margin $303 13% % of Revenues 44.6% 24 bps SG&A $125 - 37% % of Revenues 18.5% - 1471 bps R&D $56 12% % of Revenues 8.2% - 5 bps Operat
Slide 18: Varian consolidated (non-GAAP) Key P&L Financial Metrics
VARIAN FISCAL 2018 $M 1Q Y/Y Gross Orders $666 15% Revenues $679 13% Product $366 18% Services $313 7% Gross Margin $304 13% % of Revenues 44.8% 22 bps SG&A $122 - 18% % of Revenues 18.0% - 689 bps R&D $56 12% % of Revenues 8.2% - 5 bps Operating Earnings $126 84% 1 % of Revenues 18.6% 716 bps EPS (
Slide 19: Tax Cuts and Jobs Act impact on first quarter results
$0.0 $50.0 $100.0 $150.0 $200.0 $250.0 GAAP Tax on Earnings Impact of Mandatory Repatriaton of Unremitted Foreign Earnings Impact of Re- Measurment on Deferred Tax Assets Non-GAAP Tax on Earnings Tax Cuts and Jobs Act enactment Impact on First Quarter Fiscal Year 2018 Results The ‘Tax Cuts and Jobs
Slide 20: Key Balance Sheet and Cash Flow Metrics
Varian consolidated Key Balance Sheet and Cash Flow Metrics • Cash Flow from Operations more than doubled driven by operating income growth and working capital improvements Oncology DSO down from 108 to 103 days • Continuing to strengthen financial flexibility through operational execution and by st
Slide 21: Oncology operating segment Key Financial Metrics
Oncology operating segment Key Financial Metrics • Strong start to the year with orders growth at nearly 7%, with growth in all regions Oncology orders mix: North America 45%, International 55% 12 new orders for Halcyon in the quarter; 19 new orders for HyperArc • Product revenue growth of 20% drive
Slide 22: Oncology gross orders by geography
Oncology gross orders by geography AMERICAS 2% 1Q Y/Y APAC 6% 1Q Y/Y EMEA 19% 1Q Y/Y 22
Slide 23: Particle Therapy operating segment Key Financial Metrics
Particle Therapy operating segment Key Financial Metrics • 2 new orders of ProBeam ® Compact systems, both in the Americas region University of Alabama University of Miami • 4 th quarter in a row with 2 Proton orders • 7 operational sites with 24 rooms in 5 countries; 16 more sites in progress acros
Slide 24: ProBeam proton therapy system sites
ProBeam proton therapy system sites 23 ProBeam Sites Rooms Operational Centers Centers Under Development 70 24
Slide 25: FY 2018 Guidance
FY 2018 Guidance
Slide 26: Updated Fiscal Year 2018 Guidance
Varian consolidated Updated Fiscal Year 2018 Guidance Raising full fiscal year 2018 guidance after considering the following: • Stronger radiation therapy market performance; stronger performance of Varian in the market • Implementation of the Tax Cuts and Jobs Act 26 VARIAN $M FY16 Actual FY17 Actu
Slide 27: 1Q FY 2018 Financial Overview
1Q FY 2018 Financial Overview
Slide 28: Non-GAAP disclosure
Non - GAAP disclosure 28 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted
Slide 29: GAAP to non-GAAP reconciliation
GAAP to non - GAAP reconciliation 29 (1) Includes $1.3 million, $1.2 million, $1.2 million, $1.3 million and $1.2 million, respectively in cost of revenues for the pe rio ds presented. (2) Other includes acquisition - related expenses and benefits. (3) Represents the tax effect of a change in law re
Slide 30: Total revenues by sales classification
Total revenues by sales classification 30 CC – Constant currency $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Product revenues $309.2 $364.9 $326.2 $402.8 $365.6 Y/Y 18% Service revenues $292.3 $298.3 $306.6 $319.0 $312.9 Y/Y 7% Total revenues $601.5 $663.2 $632.8 $721.8 $678.5 Y/Y 13% Y/Y – CC 11% Pr
Slide 31: Total revenues by region
Total revenues by region 31 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Americas revenues $298.2 $341.6 $336.3 $368.6 $356.7 Y/Y 20% Y/Y – CC 20% EMEA revenues $184.0 $185.3 $169.5 $220.4 $193.0 Y/Y 5% Y/Y – CC - 2% APAC revenues $119.3 $136.3 $127.0 $132.8 $128.8 Y/Y 8% Y/Y – CC 10% Total revenues $
Slide 32: Total Oncology revenues by sales classification
Total Oncology revenues by sales classification 32 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Product revenues $282.4 $334.8 $259.7 $353.7 $338.3 Y/Y 20% Y/Y – CC 18% Service revenues $288.8 $297.1 $304.7 $315.6 $311.1 Y/Y 8% Y/Y – CC 6% Total revenues $571.2 $631.9 $564.4 $669.3 $649.4 Y/Y 14% Y/Y
Slide 33: Total Oncology revenues by region
Total Oncology revenues by region 33 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Americas revenues $290.8 $332.0 $286.9 $347.1 $337.4 Y/Y 16% Y/Y – CC 16% EMEA revenues $169.0 $167.5 $157.6 $196.9 $183.5 Y/Y 9% Y/Y – CC 2% APAC revenues $111.4 $132.4 $119.9 $125.3 $128.5 Y/Y 15% Y/Y – CC 17% Total re
Slide 34: Total Particle Therapy revenues by sales classification
Total Particle Therapy revenues by sales classification 34 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Product revenues $26.8 $30.1 $66.5 $49.1 $27.3 Y/Y 2% Service revenues $3.5 $1.2 $1.9 $3.4 $1.8 Y/Y - 49% Total revenues $30.3 $31.3 $68.4 $52.5 $29.1 Y/Y - 4% VPT revenues as a percentage of total
Slide 35: Oncology gross orders by region
Oncology gross orders by region 35 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Americas orders $293.6 $335.2 $331.9 $479.0 $299.5 Y/Y 2% Y/Y – CC 2% EMEA orders $160.1 $180.3 $204.5 $315.4 $190.4 Y/Y 19% Y/Y – CC 13% APAC orders $123.0 $119.5 $151.3 $153.0 $130.0 Y/Y 6% Y/Y – CC 6% Total orders $576.
Slide 36: Our promise: People powering victories
Our promise 36 People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer
Varian Medical Systems — Q1 2018 Earnings Presentation on 6ix